Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in 143 Phase III Trials
Katsuyuki Hotta, Yoshiro Fujiwara, Katsuyuki Kiura et al. · Journal of Thoracic Oncology · 2007
Cited by 71 works. doi:10.1097/01.jto.0000268673.95119.c7 Open-access PDF
Authors
- Katsuyuki Hotta
- Yoshiro Fujiwara
- Katsuyuki Kiura
- Nagio Takigawa
- Masahiro Tabata
- Hiroshi Ueoka
- Mitsune Tanimoto
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
- Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
- Molecular insights into cancer invasion: strategies for prevention and intervention.
- Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599